吃瓜不打烊

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Healthcare Helpline
    • 吃瓜不打烊 Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • Common Ground
    • Diagnosis: Debt
    • The Body Shops
    • Priced Out
    • Guns, Race, and Profit
    • Broken Rehab
    • Dead Zone
    • Denied
    • Opioid Settlement Tracking
    • Eleven Minutes
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Healthcare Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health
    All Topics

  • Medicare Advantage Billing Probe
  • School Vaccine Mandates
  • Weight Loss Drugs Coverage
  • Opioid Settlement Money
  • Abortion Pill Access

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Dec 6 2023

Full Issue

Perspectives: What's Causing So Many Drug Shortages?; Smart-Bomb Cancer Drugs Prove Effective

Read recent commentaries about pharmaceutical issues.

There鈥檚 been a bombardment of bad news for drug supplies. The American Society of Health-System Pharmacists found this summer that nearly all of the members it surveyed were experiencing drug shortages, which generally affect half a million Americans. (Emily Tucker, 12/6)

Cancer drugs that work like heat-seeking missiles to deliver chemicals directly to tumors are having a bit of a moment. Pharmaceutical companies, in need of assets to counter flagging sales, are making these so-called antibody-drug conjugates the technology of choice in oncology dealmaking, as illustrated by last week鈥檚 $10.1 billion acquisition of ImmunoGen Inc. by AbbVie Inc. (Lisa Jarvis, 12/5)

Ozempic and other weight loss drugs are a new vista for the treatment of obesity. However, there is still much to learn. (Cory Franklin and Robert Weinstein, 12/3)

I keep reading horrifying stories of tragedy and loss at the hands of fentanyl. It happened again. 鈥淐SI Miami鈥 actor Evan Ellingson died of an accidental overdose in early November. It鈥檚 the second time his family had to bury a child after an opioid tragedy. I鈥檓 left to think that overdose-reversing nasal spray Narcan is the new CPR 鈥 giving America the power to save lives. (Sterling Elliott, 12/6)

On Monday, the Supreme Court heard arguments in the complex bankruptcy case of Purdue Pharma, whose owners, the Sackler family, have become synonymous with the carnage wreaked on American families by the profligate and dishonest marketing and distribution of OxyContin and other opioids. (Robin Abcarian, 12/6)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Friday, July 31
  • Thursday, July 30
  • Wednesday, July 29
  • Tuesday, July 28
  • Monday, July 27
  • Friday, July 24
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • 吃瓜不打烊
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

漏 2026 KFF